Distribution to Pharmacy-based Clinics and Long-term Care Pharmacies
Test to Treat
The federal government has invested in a medicine cabinet of COVID-19 treatments, which includes two oral antiviral pills – Pfizer’s Paxlovid and Merck’s Lagevrio (molnupiravir) – that can help prevent severe illness and hospitalization when taken soon after symptom onset.
Effective March 7, 2022 ASPR began distributing oral antiviral pills directly to participating Test to Treat pharmacy-based clinics, making more treatments available to more eligible people in more locations.
Participating locations provide access for people to get tested, receive a prescription from a health care provider, and have their prescription filled - all at one convenient location.
- ASPR will also open direct ordering of oral antivirals to long-term care pharmacies to facilitate increased access for long-term care residents who are at increased risk for developing severe COVID-19.
- The Test to Treat initiative builds upon the existing distribution of oral antivirals to thousands of locations across all states and territories and 200 HRSA-funded community health centers nationwide.
While vaccination continues to provide the best protection against COVID-19, the Test to Treat initiative is part of a broader strategy to quickly connect eligible individuals who are at high risk of getting very sick from COVID-19 to treatments.
Building upon the existing distribution of oral antivirals to thousands of locations across all states and territories, the Test to Treat initiative is part of a broader strategy to quickly connect eligible individuals who are at high risk of getting very sick from COVID-19 to appropriate treatments. The Department of Veterans Affairs (VA) is also connecting our nation’s veterans at VA medical centers directly to treatment.
